Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Hanmi Financial Corp publishes a filing, an earnings call transcript or a press release.

Get HAFC alerts

About Anthony Kim

Earlier roles on record: CFO at Marker Therapeutics, Inc. (MRKR) until September 30, 2022. Marker Therapeutics, Inc. reported in an 8-K filed September 27, 2022 that Anthony Kim was terminated as Chief Financial Officer, effective September 30, 2022. The proxy statement of Hanmi Financial Corp reports total compensation of $670,511 for Anthony Kim in fiscal 2023, including a base salary of $348,693. Disclosed compensation is on record for 5 fiscal years. Anthony Kim has spoken on 6 earnings calls and 1 other investor event across 2 companies, most recently for Hanmi Financial Corp on October 27, 2026. Those appearances were for Hanmi Financial Corp (HAFC) and Marker Therapeutics, Inc. (MRKR). Hanmi Financial Corp is classified in the Banks - Regional industry within the Financial Services sector. Other companies whose calls Anthony Kim spoke on are classified in the Healthcare sector. Other leadership on record at Hanmi Financial Corp includes Bonita I. Lee (CEO and Board Member), C. G. Kum (CEO), Joseph A. Pangrazio (Chief Accounting Officer) and 7 others.

“the Company had separated Anthony Kim, Chief Financial Officer of the Company, effective September 30, 2022, as part of the Company's capital conservation measures.”
Marker Therapeutics, Inc. Form 8-K, filed September 27, 2022 · Read the filing

Anthony Kim on recent calls

“I'll begin by providing additional details on our loan productions. Third quarter loan production was $544 million, up $172 million, or 46.2%, from the prior quarter, with a weighted average interest rate of 6.61%, compared to 6.59% last quarter.”
Other, Q3 Earnings Conference Call ·
“I'll begin by providing additional details on our loan production. Second quarter loan production was $372 million, down $6 million, or 1.6% from the prior quarter, with a weighted average interest rate of 6.59% compared to 6.54% last quarter.”
Other, 2026 KBW Summer Bank Conference ·
“I will begin by providing additional details on our loan production. Second quarter loan production was $372 million, down $6 million or 1.6% from the prior quarter with a weighted average interest rate of 6.59% compared to 6.54% last quarter.”
Other, Hanmi Financial Corp Q2 FY2026 Earnings Call ·
“I'll begin by providing additional details on our loan production. First quarter loan production was $378 million, up $3 million, or 0.8% from the prior quarter, with a weighted average interest rate of 6.54% compared to 6.90% last quarter.”
Other, Hanmi Financial Corp Q1 FY2026 Earnings Call ·
“I will begin by providing additional details on our loan production. Fourth-quarter loan production was $375 million, down $196 million, or 34%, from the prior quarter, with a weighted average interest rate of 6.90%, compared to 6.91% last quarter.”
Other, Hanmi Financial Corp Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Hanmi Financial Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Hanmi Financial Corp (HAFC) $348,693 $670,511
2022 Marker Therapeutics, Inc. (MRKR) $330,370 $929,170
2022 Hanmi Financial Corp (HAFC) $313,154 $638,997
2021 Marker Therapeutics, Inc. (MRKR) $400,754 $948,291
2021 Hanmi Financial Corp (HAFC) $291,158 $569,575
2020 Marker Therapeutics, Inc. (MRKR) $392,906 $829,306
2020 Hanmi Financial Corp (HAFC) $277,432 $423,314
2019 Marker Therapeutics, Inc. (MRKR) $375,000 $431,523

Recent activity